Moderna shares see a dip: what is pressuring the stock

Traders Union
All News
Financial News
Moderna slides 3.77% today to $51.90

Highlights

Moderna posted earnings ahead of expectations, while the FDA initiated a review of its mRNA flu vaccine candidate.
Militia Capital Partners LP decreased exposure by selling 49,000 shares as updated COVID-19 vaccine data showed moderate protection against severe illness.
Despite prevailing selling pressure, medium- and long-term technical indicators indicate a sustained bullish trend with 80% probability of an upside move toward $58.90–$59.23 next week.

Mixed fundamental signals as strong flu news meets institutional selling

Moderna reported better-than-expected earnings, accompanied by a trading volume of $370 million. The U.S. Food and Drug Administration has decided to review Moderna's mRNA flu vaccine, while Militia Capital Partners LP reduced its holdings in the company by selling 49,000 shares during the third quarter. Additionally, the updated 2024-2025 Moderna mRNA COVID-19 vaccine was reported to provide moderate protection against severe illness, including hospitalizations and emergency visits, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, highlights that Moderna's price action signals a tug-of-war between short-term sellers and resilient longer-term support. He points out that despite upbeat earnings and an FDA review, institutional outflows like Militia Capital's divestment and mixed oscillator signals create uncertainty for sustained upside. Kharitonov stresses that intraday selling pressure and divergence in technical indicators leave the stock exposed to further correction. He remains wary of relying on projected bullish corridors while the instrument lingers below the SMA-20 and shows pronounced volatility. "Without confirmation from both volume and momentum, I consider the downside risks too significant to ignore in the current setup," he concludes.

Viktoras Karapetjanc, expert at Traders Union, believes Moderna’s positive earnings surprise and FDA engagement are driving strong underlying sentiment. He notes the bullish structure remains intact, with supportive higher timeframes and robust weekly indicators in play. Karapetjanc sees further growth likely as new vaccine updates sustain demand and the projected trading range highlights upside potential. "Investors should stay alert for a breakout above $53, as momentum favors continued appreciation for MRNA," he advises.

Divergence in oscillator momentum as selling pressure intensifies intraday

Momentum on the daily timeframe stays strong, with both MACD and ADX in bullish territory, though oscillators reveal mixed conditions: RSI and CCI suggest ongoing buying interest, but Stoch RSI signals oversold conditions and BBP hints at recent overbought extremes. AO is neutral and does not currently confirm the primary trend. The stock opened slightly lower, showing a minor gap from the previous close ($53.93 to $53.35) and has since dropped 3.77% to sit near today’s low of $51.03. Intraday volatility is moderate, with clear selling pressure dominating since the open. Diverging oscillator and momentum signals underscore short-term uncertainty as intraday downside confirms recent weakness.

Previously it was reported that Moderna’s outlook turned increasingly bullish following a major legal victory and positive technical signals, with anticipation building for continued upside. The present setup introduces a layer of near-term caution due to fresh selling pressure and diverging signals, making the $53 level pivotal for confirming renewed bullish momentum in the days ahead.

Source of Data: MRNA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.